Provides advanced genomic sequencing and data analytics services, focusing on precision medicine in oncology.
Personalis, Inc. is a global leader in cancer genomics, focusing on providing comprehensive sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research initiatives. The company's flagship NeXT Platform revolutionizes cancer profiling by offering advanced data analysis of tumor and immune microenvironments from minimal tissue or plasma samples. This platform includes ImmunoID Next for tissue-based tumor profiling, NeXT Liquid Biopsy for plasma-based tumor profiling, and NeXT Personal, a liquid biopsy solution for personalized tumor tracking in patients.
In addition to its NeXT Platform, Personalis, Inc. offers the NeXT Dx Test, a genomic cancer profiling test that identifies composite biomarkers critical for personalized cancer treatment strategies. The company also leverages its ACE platform for clinical and therapeutic applications, including neoantigen prediction, biomarker discovery, and the identification of novel drug targets. Serving a diverse clientele that includes biopharmaceutical companies, universities, non-profits, and government entities, Personalis collaborates with renowned institutions such as Mayo Clinic, MapKure, SpringWorks Therapeutics, and Moores Cancer Center.
Founded in 2011 and headquartered in Menlo Park, California, Personalis, Inc. continues to drive innovation in cancer genomics, enhancing precision medicine approaches through its cutting-edge technologies and strategic partnerships. With a commitment to advancing cancer research and improving patient outcomes, the company remains at the forefront of genomic profiling and personalized medicine solutions worldwide.